Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04164732 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT04164732 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT04164732, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if LCZ696 can improve functional capacity (via improved peak VO2) in non-obstructive hypertrophic cardiomyopathy (HCM) patient population over the course of 50 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG LCZ696
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-01-08 |
| Est. Completion | 2023-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04164732
The ClinicalTrials.gov registry entry for NCT04164732 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04164732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04164732 about?
NCT04164732 is a clinical study titled "Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy". The purpose of this study was to determine if LCZ696 can improve functional capacity (via improved peak VO2) in non-obstructive hypertrophic cardiomyopathy (HCM) patient population over the course of 50 weeks of treatment.
What is the current status of trial NCT04164732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2020-01-08. Estimated completion is 2023-08-22.
What interventions are being tested in trial NCT04164732?
The interventions under investigation include: Placebo (DRUG), LCZ696 (DRUG).
Who is sponsoring clinical trial NCT04164732?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.